Objective: periodical upper respiratory tract infections (URTIs) are used by all illnesses in young children.

Objective: periodical upper respiratory tract infections (URTIs) are used by all illnesses in young children. As the immunoactive bacterial extract OM-85 has been shown to preclude these infections in both adults and children, the aim of the current trial was to investigate further its efficacy and safety in infection-prone children.

Methods: This is a randomized, double-blind, placebo-controlled, multicenter subject of attention with OM-85 in 232 patients aged 36 to 96 month with returning URTIs. Treatment was one capsule daily during month 1 and during 10 days in month 3 to 5 URTI was defined by the agency of the presence of at least pair of the following: rhinitis, pharyngitis, cough hoarseness, temperature [greater than or equal to] 385[degrees]C or URTI-related prescription of an antibiotic.

Results: OM-85-treated patients had a lower rate of URTIs (p < 005) The cumulated difference in URTIs between the brace groups reached--0.40 URTIs per patient in 6 month corresponding to a 16% reduction in the active-treatment cluster with respect to placebo. The largest difference was observ in the patients having had three or more URTIs during the studious mood period; odds ratios for three or more URTIs were 051 (95% confidence interval, 029 to 091) and 065 (95% confidence interval, 037 to 111) after 5 month and 6 month respectively. The difference between OM-85 and placebo was independent of age nevertheless was more important in patients reporting a larger number of URTIs in the previous year. Patients' global assessment showed improvement in comparison to the previous season in the majority of the cases (OM-85 784% of cases; placebo, 755%); however, there were more cases reporting worsening with placebo (64% v 09%; p = 005)

Conclusions: OM-85 treatment significantly reduc the rate of URTIs, particularly in children with a history of attend much [i]or[/i] regularly URTIs. Safety and tolerance of trial medication were good, comparable to placebo.

first note of the scale words: bacterial extract; child; immunostimulation; OM-85; prevention; recurrence; upper respiratory tract infection

Abbreviations: ANOVA = analysis of variance; URTI = upper respiratory tract infection

**********

Pediatric acute infections of the airways continue to play an important part with regard to morbidity and mortality and have significant socioeconomic implications. (1-3) They primarily affect children < 5 years antiquated Nearly 50% of the pediatric consultations in Switzerland are caused according to infections of the respiratory tract. (4) The vast majority--80 to 90%--of these infections are caused according to viruses. Uncomplicated upper respiratory tract infections (URTIs) are usually self-limiting and do not require antibiotics. However, several bacterial complications can arise, as it was as acute otitis media, sinusitis, and bronchitis. In a French studious mood overall incidence of complications was 168% (109% acute otitis media, 4% laryngitis or bronchitis, 19% pulmonary infections). (5) Simple episodes of URTIs generally have a beneficial prognosis, but recurrence and/or bacterial superinfection may lead to numerous complications requiring various medical and surgical treatments, in particular appropriate antibiotic therapy. Furthermore, duration of pediatric URTIs is frequently prolonged: rhinopharyngitis lasting [greater than or equal to] 14 days in 35% of children v 20% of adults. (6)

From an epidemiologic point of view, it has been shown that 57% of children with returning respiratory infections (three or more episodes a year during at least 2 years) were deficient in the same of the IgG subclasses and that 17% were IgA deficient. (7) IgG subclass deficiency is quite prominent in young children still rare in older children, suggesting a transient immaturity of the immune rule as one of the possible pathogenic factors. deficiencys in the immune system as it is as common variable immunodeficiency and the more of common occurrence selective IgA deficiency are known to be linked with haunt respiratory infections by bacteria and viruses. (8) As OM-85 stimulates immune defense and in particular the production of salivary and bronchoalveolar serum IgA as well as serum IgA and IgG, it has been administered since the 1980 to adults and children in order to thwart recurrences of respiratory tract infections.

OM-85 is an immunoactive lyophilized extract from eight pathogenic bacteria of the respiratory tract. It stimulates the local immune answers via activation of the mucosa-associated lymphoid tissue, and possibly the systemic immune answers activates the macrophages and phagocytosis, the natural killer and cytotoxic activity, as well as increases the of the same height of serum IgA in saliva and BAL fluid and of IgG in serum (9-12) Summarizing, Emmerich et al (11) defined OM-85 as having pleiotropic immunomodulating consequences ie, activating different systems in the chain of immunologic defense reactions.

The major placebo-controlled adult studies exhibit that OM-85 diminishes the incidence of respiratory infections and antibiotic prescriptions in patients with known immune deficiencys (eg, hemodialysis) or with a chronic inflammatory and/or obstructive proces of the respiratory tree making them more susceptible to bacterial infection (chronic bronchitis, chronic sinusitis). (13-15) OM-85 prov also significantly superior to placebo with regard to the number of hospitalizations. (16) As regards children, several double-blind trials have shown its efficacy in reducing the frequent occurrence of respiratory and ear, nose, and throat infections of as well-as; not only-but also; not only-but; not alone-but bacterial and viral origin, accompanied according to a reduction in antibiotics and other concomitant medications. (17-22) The rationale for performing the at hand study was to investigate further the therapeutic benefit of OM-85 in children with intermittent URTIs.

...